Direct-to-Consumer (DTC) Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomic Testing, Skincare Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) chips,

Direct-to-Consumer (DTC) Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomic Testing, Skincare Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) chips, Whole Genome Sequencing (WGS)), By Distribution Channel (Online Platforms, Over-the-Counter), Industry Analysis Report, Regional Outlook, Growth Potential, Covid-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2028

The direct-to-consumer genetic testing market is set to witness lucrative expansion through 2028 owing to rising prevalence of genetic diseases across the globe. In addition, growing public acceptance and surging awareness pertaining to genetic testing, coupled with mounting demand for personalized services without direct involvement of a healthcare provider, are anticipated to further drive the growth of the industry over the forecast timeline.

Recently, technological advancements have created massive opportunities for product penetration. Moreover, increasing number of chronic diseases, along with the launch of personalized testing kits on online platforms, has also positively influenced the product landscape.

Notably, industry players have been focusing on product innovation to gain a competitive edge in the direct-to-consumer genetic testing market, thereby fueling business growth. For instance, in January 2022, 23andMe, a major consumer genetics firm, received 510(k) clearance from the U.S. FDA for a test that detects a hereditary marker for prostate cancer. The test gives information on the presence of the G84E mutation in the user’s HOXB13 gene, which has been shown to increase the risk of prostate cancer.

Overall, the direct-to-consumer genetic testing market has been segregated in terms of test type, technology, distribution channel, and region. With reference to test type, the market has been classified into predictive testing, carrier testing, skincare testing, ancestry and relationship testing, and nutrigenomic testing. Among these, the nutrigenomic testing segment garnered a revenue of over USD 315 million in 2021 and is poised to exhibit sturdy growth over 2022-2028. The growth of this segment is mainly due to increasing awareness about health and wellness in people.

On the basis of technology, the direct-to-consumer genetic testing market has been segmented into targeted analysis, whole genome sequencing (WGS), and single nucleotide polymorphism (SNP) chips. The targeted analysis technology segment is likely to depict a CAGR of approximately 14.5% through the analysis timeframe owing to notable advancements in the technology for the diagnosis of different diseases.

Based on distribution channel, the market has been bifurcated into over-the-counter and online platform. In 2021, the online platform segment reached a valuation of nearly USD 1 billion and is set to observe considerable growth over the forecast period. Ease of conducting online business with a wide range of products is primed to drive segmental growth in the coming years.

From the regional point of view, the Latin America direct-to-consumer genetic testing industry accounted for a market share of around 10.5% in 2021 and is primed to witness robust growth through 2028. Soaring public awareness regarding direct-to-consumer genetic testing in the region is estimated to foster market outlook.